Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy

Next Previous
Trial Profile

A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edasalonexent (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms MoveDMD
  • Sponsors Astria Therapeutics; Catabasis Pharmaceuticals

Most Recent Events

  • 28 Sep 2020 Results presented in a Catabasis Pharmaceuticals media release.
  • 28 Sep 2020 According to a Catabasis Pharmaceuticals media release, long-term safety results from this trial and open-label extension were presented at the Virtual 25th International Congress of the World Muscle Society.
  • 12 May 2020 According to a Catabasis Pharmaceuticals media release, data from an analysis of the baseline characteristics of patients enrolled in the Phase 3 PolarisDMD trial, age-normative growth and normal adrenal function seen in the Phase 2 MoveDMD trial presented at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top